Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report

Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report

Abstract Background Atypical BCR-ABL1 transcripts are detected in less than 5% of patients diagnosed with chronic myeloid leukaemia (CML), of which e19a2 is the most frequently observed, with breakpoints in the micro breakpoint cluster region (μ-BCR) and coding for the p230 BCR-ABL1 protein. p230 CM...

Full description

Bibliographic Details
Main Authors: Nuno Cerveira, Rosa Branca Ferreira, Susana Bizarro, Cecília Correia, Lurdes Torres, Susana Lisboa, Joana Vieira, Rui Santos, Fernando Campilho, Carlos Pinho Vaz, Luís Leite, Manuel R. Teixeira, António Campos
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Cancer
Subjects:
CML
T315I
Relapse
HSCT
Ponatinib
Online Access:http://link.springer.com/article/10.1186/s12885-018-5100-4

Internet

http://link.springer.com/article/10.1186/s12885-018-5100-4

Similar Items